Persister state-directed transitioning and vulnerability in melanoma
Heike Chauvistré(Essen University Hospital), Alexander Roesch(Essen University Hospital), Antonio Sechi(RWTH Aachen University), Renáta Váraljai(Vrije Universiteit Brussel), Susanne Horn(Vrije Universiteit Brussel), Samantha J. Stehbens(The University of Queensland), Felix C. E. Vogel(German Cancer Research Center), Batool Shannan(Vrije Universiteit Brussel), Markus Kaiser(Essen University Hospital), Meenhard Herlyn(The Wistar Institute), Dirk Schadendorf(National Center for Tumor Diseases), Iris Helfrich(German Cancer Research Center), Clemens Krepler(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kirujan Jeyakumar(TU Dortmund University), Oliver Keminer(Fraunhofer Institute for Translational Medicine and Pharmacology), Annette Paschen(University of Duisburg-Essen), Marc Remke(Saarland University), Sheraz Gul(Fraunhofer Institute for Translational Medicine and Pharmacology), Nikolas K. Haass(The University of Queensland), Stefanie Egetemaier, Linda Kubat(Essen University Hospital), Jürgen C. Becker(Düsseldorf University Hospital), Jan Förster(Essen University Hospital), Daniel Rauh(TU Dortmund University), Farnusch Kaschani(University of Duisburg-Essen), Michael Ehrmann(Center for Economic and Policy Research), Daniel Picard(Heidelberg University), José Neptuno Rodríguez‐López(Universidad de Murcia), Vito W. Rebecca(Johns Hopkins University), Qin Liu(University of Science and Technology of China), Xiangfan Yin(The Wistar Institute), Robert J. Ju(The University of Queensland), Sheena M. Daignault(The University of Queensland), Smiths Lueong(German Cancer Research Center)
Cited by 4
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
|Journal of Clinical Oncology|2015|2.1k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k